About this trial
To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
All children with asthma diagnosis accord with the GINA in 2023 edition;
Other diseases that could cause wheezing and cough were excluded, such as acute laryngitis, diphtheria, congenital airway abnormalities, and tracheal foreign bodies;
In front of the hospital 2 weeks without antibiotics, systemic hormone medication history;
There were no other complications, such as congenital heart disease, pneumonia, gastroesophageal reflux disease, muscle dysplasia, etc.
Disqualifiers
Children who had taken immunosuppressants, antibiotics and other drugs for a long time before admission;
Children with primary immunodeficiency disease;
The children and their families failed to cooperate or refused the experimental observation.
Trial population
Children with asthma, aged 3-14 years, attending our hospital.
Trial design
Case-control
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
type 2 inflammation indicators
Fraction of exhaled nitric oxide(FeNO)、Blood eosinophil count、Percentage of sputum eosinophils and Serum total immunoglobulin E
pulmonary function indicators
Forced expiratory volume in one second(FEV1)、Forced vital capacity(FVC)、Ratio of forced expiratory volume in one second to forced vital capacity(FEV1/FVC) and Peak expiratory flow(PEF)
single nucleotide polymorphism
Differences in SNPs of genes detected in children's blood samples
Sponsors and contacts
Click on the lead sponsor to view all of their trials.